ATAI
HEALTHCAREATAI Life Sciences N.V.
$4.17+0.17 (+4.25%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving ATAI Today?
No stock-specific AI insight has been generated for ATAI yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$1.38$6.75
$4.17
Fundamentals
Market Cap$1.5B
P/E Ratio—
EPS$-2.91
Dividend Yield—
Dividend / Share—
ROE-3.9%
Profit Margin—
Debt / Equity—
Trading
Volume3.9M
Avg Volume (10D)—
Shares Outstanding366.9M
ATAI News
22 articles- Does AtaiBeckley’s (ATAI) EMP-01 Data Hint At A Scalable MDMA Therapy Platform?Yahoo Finance·May 1, 2026
- These 3 Psychedelic Stocks Activated After Trump's Executive OrderMarketbeat·Apr 27, 2026
- AtaiBeckley wins OVID Health Silver Award for patient partnership in psychedelic trialsProactive Investors·Apr 27, 2026
- AtaiBeckley and PsyPAN Receive a Silver Award in 2026 Patient Participant Index, Reflecting Ongoing Commitment to Participant-Informed ResearchYahoo Finance·Apr 27, 2026
- FDA Fast-Tracks Review of Some Psychedelic Drugs. This Stock Is Set to Benefit.Yahoo Finance·Apr 24, 2026
- Psychedelic Pharma Stocks Are Riding High. Past Cannabis Returns Are a Reality Check.Yahoo Finance·Apr 24, 2026
- FDA Fast-Tracks Psychedelic Drug Research Following Trump Directive; Psychedelic Drug Makers GainYahoo Finance·Apr 24, 2026
- Atai Beckley (ATAI): The Best Penny Stock to Buy and Hold Under $5Yahoo Finance·Apr 23, 2026
- ‘Can I have some, please?’: Trump jokes as he signs psychedelics order after Joe Rogan push. These stocks soarYahoo Finance·Apr 22, 2026
- What’s Guggenheim Updates View on AtaiBeckley Inc (ATAI)?Yahoo Finance·Apr 22, 2026
- AtaiBeckley Announces Additional Phase 2a Results for EMP-01 (oral R-MDMA) Showing Large and Consistent Improvements in Social Anxiety DisorderGlobeNewswire Inc.·Apr 22, 2026
- Is It Too Late To Consider AtaiBeckley (ATAI) After A 231% One-Year Rally?Yahoo Finance·Apr 22, 2026
- Guggenheim Lifts PT on AtaiBeckley Inc. (ATAI) to $16 From $11Yahoo Finance·Apr 20, 2026
- Trump Signed a Psychedelic Drugs Order—and These 4 Stocks SurgedYahoo Finance·Apr 20, 2026
- This 4/20, Wall Street Is Betting on More Than MarijuanaMarketbeat·Apr 20, 2026
- Psychedelics stocks rise after Trump order expands research, access pathwaysProactive Investors·Apr 20, 2026
- Psychedelic Shares Rise Following Trump's Executive Order to Accelerate Treatments for Serious Mental IllnessYahoo Finance·Apr 20, 2026
- Psychedelic stocks soar after Trump signs executive order to fast-track treatmentsYahoo Finance·Apr 20, 2026
- Trump Trade: President to sign order on psychedelic used for PTSDYahoo Finance·Apr 17, 2026
- AtaiBeckley’s BPL-003 Depression Data Sharpen Clinical Path And Investor FocusYahoo Finance·Apr 16, 2026
- Johnson & Johnson’s Spravato sales growth signals upside for psychedelics peersProactive Investors·Apr 14, 2026
- AtaiBeckley to Participate in Upcoming Needham Healthcare ConferencesGlobeNewswire Inc.·Apr 14, 2026
All 22 articles loaded
Price Data
Open$4.01
Previous Close$4.00
Day High$4.24
Day Low$3.99
52 Week High$6.75
52 Week Low$1.38
52-Week Range
$1.38$6.75
$4.17
Fundamentals
Market Cap$1.5B
P/E Ratio—
EPS$-2.91
Dividend Yield—
Dividend / Share—
ROE-3.9%
Profit Margin—
Debt / Equity—
Trading
Volume3.9M
Avg Volume (10D)—
Shares Outstanding366.9M
About ATAI Life Sciences N.V.
ATAI Life Sciences is a pharmaceutical company that is developing psychedelics, other hallucinogens, entactogens, and related drugs for treatment of psychiatric conditions. It was founded in 2018 and is headquartered in Berlin, Germany.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—